Ratings Vext Science, Inc.




Market Closed - Canadian Securities Exchange 20:11:01 16/07/2024 BST 5-day change 1st Jan Change
0.24 CAD -1.03% Intraday chart for Vext Science, Inc. +4.35% -17.24%


  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.


  • One of the major weak points of the company is its financial situation.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
-17.24% 43.56M -
+19.34% 228M -
+37.79% 177M
-15.46% 173M -
+270.00% 121M - -
+31.11% 112M -
+88.45% 109M - -
-51.20% 98.86M
-28.57% 97M - -
+7.69% 80.38M - -
Investor Rating
Trading Rating
ESG Refinitiv


Sales growth
Earnings Growth
EBITDA / Sales


P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow


1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision


Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. VEXT Stock
  4. Ratings Vext Science, Inc.